---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135263"
form_type: "8-K"
ticker: null
cik: "0001828522"
company_name: "eFFECTOR Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:56:06.596328+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# eFFECTOR Q1 net loss $8.8M; tomivosertib NSCLC fails; zotatifin advance

## Summary
- Net loss of $8.8M ($2.16 per share) vs $10.0M ($5.96 per share) in Q1 2023.
- Cash, equivalents, and short-term investments $25.4M at March 31, 2024; raised $15M in Jan 2024 registered direct offering.
- Zotatifin ZFA triplet dose escalation at 0.14 mg/kg; RP2D expected H2 2024.
- Tomivosertib KICKSTART trial in NSCLC: HR 0.62 (p=0.21), missed pre-specified 0.2 threshold; no path forward.
- R&D expense decreased to $5.3M from $6.6M; cash runway into Q1 2025.

## SEC filing metadata
- accession: 0001193125-24-135263
- form_type: 8-K
- cik: 0001828522
- company_name: eFFECTOR Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/0001193125-24-135263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/d822499d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135263
- JSON: https://secwatch.observer/filing/0001193125-24-135263.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135263.txt

## Key facts
- Earnings Releases
  eFFECTOR Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524135263/0001193125-24-135263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.